Creative Planning Takes $257,000 Position in Amedisys Inc (AMED)

Creative Planning purchased a new stake in shares of Amedisys Inc (NASDAQ:AMED) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,057 shares of the health services provider’s stock, valued at approximately $257,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. BlackRock Inc. grew its holdings in Amedisys by 7.5% during the second quarter. BlackRock Inc. now owns 5,382,005 shares of the health services provider’s stock valued at $459,945,000 after purchasing an additional 377,153 shares during the period. Rothschild Asset Management Inc. grew its holdings in Amedisys by 0.3% during the second quarter. Rothschild Asset Management Inc. now owns 447,262 shares of the health services provider’s stock valued at $38,223,000 after purchasing an additional 1,278 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in Amedisys by 9.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 202,546 shares of the health services provider’s stock valued at $17,310,000 after purchasing an additional 16,677 shares during the period. Acadian Asset Management LLC grew its holdings in Amedisys by 148.0% during the second quarter. Acadian Asset Management LLC now owns 191,162 shares of the health services provider’s stock valued at $16,338,000 after purchasing an additional 114,077 shares during the period. Finally, Sei Investments Co. grew its holdings in Amedisys by 762.0% during the second quarter. Sei Investments Co. now owns 123,582 shares of the health services provider’s stock valued at $10,562,000 after purchasing an additional 109,246 shares during the period. 93.58% of the stock is owned by institutional investors.

Several equities analysts have weighed in on AMED shares. SunTrust Banks increased their price objective on Amedisys to $130.00 and gave the company a “buy” rating in a report on Thursday, October 11th. Bank of America set a $139.00 price target on Amedisys and gave the stock a “buy” rating in a report on Tuesday, September 18th. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 16th. Benchmark raised Amedisys from a “hold” rating to a “buy” rating and set a $125.00 price target for the company in a report on Tuesday, October 30th. Finally, Craig Hallum lowered Amedisys from a “buy” rating to a “hold” rating and cut their price target for the stock from $116.00 to $104.00 in a report on Friday, October 26th. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Amedisys currently has a consensus rating of “Buy” and a consensus target price of $105.50.

In related news, insider David L. Kemmerly sold 6,500 shares of Amedisys stock in a transaction on Friday, November 9th. The stock was sold at an average price of $118.87, for a total transaction of $772,655.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David B. Pearce sold 398 shares of Amedisys stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total value of $48,440.58. Following the sale, the insider now directly owns 11,818 shares of the company’s stock, valued at approximately $1,438,368.78. The disclosure for this sale can be found here. Insiders have sold 10,273 shares of company stock valued at $1,217,456 in the last three months. 2.60% of the stock is owned by corporate insiders.

Amedisys stock opened at $120.50 on Friday. Amedisys Inc has a one year low of $49.80 and a one year high of $127.38. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06. The firm has a market capitalization of $3.57 billion, a PE ratio of 54.52, a P/E/G ratio of 1.67 and a beta of 1.22.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Monday, October 29th. The health services provider reported $0.95 EPS for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.18. Amedisys had a return on equity of 23.27% and a net margin of 5.39%. The firm had revenue of $417.34 million during the quarter, compared to analyst estimates of $411.05 million. During the same period last year, the company earned $0.56 earnings per share. The business’s revenue for the quarter was up 11.7% on a year-over-year basis. Analysts anticipate that Amedisys Inc will post 3.58 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Creative Planning Takes $257,000 Position in Amedisys Inc (AMED)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/11/10/creative-planning-takes-257000-position-in-amedisys-inc-amed.html.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Read More: Earnings Per Share (EPS)

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply